精神分裂症药效相关转运体及靶受体基因多态性的研究进展
被引量:1
摘要
精神分裂症药物治疗的效果因人而异,抗精神病药物代谢通路上相关基因的多态性影响其疗效。本文主要总结了与精神分裂症药物疗效相关的转运体和受体MDR1、DRD2、DRD3、5-HT2AR及5-HT2CR基因的多态性与抗精神病药物疗效关联性研究的进展,并简要分析了出现不一致结果的原因。
出处
《国际精神病学杂志》
2011年第2期114-117,共4页
Journal Of International Psychiatry
参考文献14
-
1Wang JS, Taylor R. Olanzapine Penetration into Brain is Greater in Transgenic Abcbla P - glycoprotein - Deficient Mice than FVB1 (Wild -Type) Animals. Neu ro psychopha rmacology, 2004: 29:551-557.
-
2KIRCHBAUM KIM, STEFAN IH. Pharmacodynamic consequences of P - glycoprotein dependent pharmacokinetics of risperidone and haloperidol in mice. Behav Brain Res. 2008; 188 (2): 298-303.
-
3NORIO YF, MANABU S. Association between muhidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: A preliminary study. Prog Neuropsychopharmacol Biol Psychiatry, 2006; 30 (2): 286-291.
-
4Alenius M, Wadeliua M, Dahl ML. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatri Res. 2008 ; 42 ( 11 ) : 884 - 893.
-
5Bozina N, Kuzman MR, Medved V. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res. 2008 ; 42 (2) : 89 - 97.
-
6Xing QH, Gao R, Li HF. Polymorphisms of the ABCBI gene are associated with the therapeutic response to risperi- done in Chinese schizophrenia patients. Pharmacogenomics, 2006; 7 (7): 987-993.
-
7Shen YC, Chen SF, Chen CH, et al. Effects of DRD2/ ANKK1 gene variations and clinical factors on aripiprazoIe ef- ficacy in schizophrenicpatients. J Psychiatric Res. 2009 ; 43 : 600-606.
-
8Kwon JS, Kim E, Kang DH, et al. TaqlA polymorphism in the dopamine D2 receptor gene as a predictor of Clinical response to aripiprazole. Eur NeuropsychopharmacoIogy, 2008; 18 (12): 897-907.
-
9Wu S, Xing Q, Gao R. Response to chlorpromazine treatment may be associated with polymorphisms Of the DRD2 gene in Chinese schizophrenic patients. Neuroscience Letters, 2005; 376:1 -4.
-
10Yamanouchi Y, lwata N, Suzuki T, et al. Effect of DRD2, 5 - HT2A, and COMT genes on antipsychotic re- sponse to risperidone. Pharmacogenomics, 2003 ; 3 : 356 - 361.
二级引证文献7
-
1王玉龙,胥欣茹,王俊晓,陈鑫,吴愚,张洪发,王燕龙.5-HTR2A基因多态性与抗精神分裂症药物疗效相关性的meta分析[J].中国现代应用药学,2022,39(2):215-223. 被引量:1
-
2司珊珊.阿立哌唑对精神分裂症患者疗效、体重及糖脂代谢的影响[J].医疗装备,2018,31(20):116-117. 被引量:3
-
3崔向波.奥氮平、氨磺必利、利培酮治疗精神分裂症的疗效[J].菏泽医学专科学校学报,2019,31(2):16-18. 被引量:12
-
4王国民,周波,金庞,倪燕飞,高晓峰.吸烟与精神分裂症患者抗精神病药物效果的相关性研究[J].中国基层医药,2020,27(9):1056-1060. 被引量:2
-
5方芳,方海红,宋明芬,闫盼,施剑飞.细胞色素P450酶1A2、2D6与多巴胺D2受体基因多态性对奥氮平治疗精神分裂症PANSS减分率的影响[J].中国现代应用药学,2020,37(13):1621-1626. 被引量:17
-
6蔡向明,杨蕾,邱建成,孙晓宇.基因检测指导下奥氮平致精神分裂症患者体质量改变的调查分析[J].实用临床医药杂志,2020,24(17):13-15. 被引量:1
-
7闫盼,宋明芬,王晟东,李静,王姝琪,汪程鹏,刘健,李欣,施剑飞.CYP1A2基因多态性对精神分裂症患者奥氮平血药浓度的影响[J].中华全科医学,2020,18(11):1851-1853. 被引量:3
-
1巴文,王磊.帕罗西汀联合小剂量齐拉西酮治疗抑郁症68例[J].中国医药指南,2016,14(19):123-123. 被引量:3
-
2高玉玲,田百玲,严颖.儿童孤独症的治疗[J].实用药物与临床,2005,8(2):42-43. 被引量:13
-
3吴勇.120例肝性脑病临床分析[J].临床医学,2005,25(2):24-25.
-
4王彦,乔妍.2型糖尿病合并脑梗塞53例临床分析[J].兵团医学,2011(4):28-29. 被引量:3
-
5欧美荣.2型糖尿病合并脑梗塞49例临床分析[J].淮海医药,2009,27(1):49-49. 被引量:10
-
6赵伟.122例急性脑梗死临床治疗分析[J].滨州医学院学报,2003,26(5):389-390.
-
7王子灿,李麟仙,方思伟.血小板活化因子在脑缺血发病中的作用[J].中国病理生理杂志,1997,13(5):526-526.
-
8孙林.海马区5-HT2AR及其mRNA表达对抑郁症发病的影响[J].中国实用乡村医生杂志,2014(13):57-58. 被引量:1
-
9赵景菊,黄朝阳.奎硫平治疗精神分裂症的临床疗效[J].中国民康医学,2008,20(10):992-992. 被引量:1
-
10李桦,吴荣琴,孙复林.无抽搐电休克治疗对精神分裂症的效果及患者认知功能的影响[J].四川精神卫生,2014,27(5):418-421. 被引量:14